3-((C12-18)-acylamino)-N-(2-((2-hydroxyethyl)amino)-2-oxoethyl)-N,N-dimethyl-1-propanaminium chloride

Basic toxicokinetics

Administrative data

Endpoint:

basic toxicokinetics in vivo

Type of information:

read-across from supporting substance (structural analogue or surrogate)

Adequacy of study:

key study

Justification for type of information:

1-Propanaminium,3-(1-oxododecyl)-amino-N-(2-((2-hydroxyethyl)amino)-2-oxoethyl)-N,N-dimethyl is an UVCB which doesn't present any alerts in genotoxicity, systemic toxicity and isn't subject to any bioaccumulation potential. Thus, a toxicokinetic study might be unrealistical since producing the benchmarks for the test is a limitating factor.

Cross-reference

Reason / purpose for cross-reference:

read-across source

Reference

Endpoint:

basic toxicokinetics in vivo

Type of information:

experimental study

Adequacy of study:

weight of evidence

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

other: Due to the cationic profile, a published article on cetrimonium bromide is a reliable data evidence to sustain our rational:

Objective of study:

toxicokinetics

Principles of method if other than guideline:

Assessing the bioavailability of a cationic surfactant using radiolabeled element

Species:

rat

Strain:

not specified

Sex:

not specified

Route of administration:

other: oral and intraveneous

Vehicle:

water

Remarks:

Due to the high water solubility

Details on exposure:

14C-labelled cetrimonium bromide: 0.8 mg/kg by oral gavage
14C-labelled laurtrimonium bromide: single intravenous injection of 0.5 ml of a 0.023% solution in saline

Preliminary studies:

The conclusion from both studies are as follows:

1)-Cetrimonium bromide shows to be poorly absorbed in the gastro-intestinal tract and not readily metabolized in the rat body.
2)-Only small amounts of radioactivity were found in other organs and there was no sign of accumulation of radioactivity in any organ.

Conclusions:

Interpretation of results (migrated information): other: Bioaccumulation is not expected
Based on the toxicological profile, one can assume that these common metabolites will be included in the physiologic processes and metabolised accordingly. Concerning excretion, an extensive metabolism, leading to polar metabolites with low molecular weights, followed by renal excretion is to be expected
Therefore there is no potential of bioaccumulation of the constituents of this mixture.

Executive summary:

The toxicokinetic evaluation of 1-Propanaminium,3-(1-oxododecyl)-amino-N-(2-((2-hydroxyethyl)amino)-2-oxoethyl)-N,N-dimethyl based both on its intrinsic profile and 2 published acticles corroborated with our assesment .

All taken togheter, one is confortable concluding that 1-Propanaminium,3-(1-oxododecyl)-amino-N-(2-((2-hydroxyethyl)amino)-2-oxoethyl)-N,N-dimethyl is not expected to bioaccumulate in the organisms.

 

Bartnik, F.G., and Wingen, F. (1979). Percutaneous absorption of dodecyltrimethylammonium bromide, a cationic surfactant, in the rat. Food Cosmet. Toxicol. 17, 633-637

Isomaa, B. (1975) Absorption, distribution and excretion of [14C]CTAB, a quaternary ammonium surfactant, in the rat. Fd. Cosmet. Toxicol. 13, 231-237

Materials and methods

Test material

Test material information

Constituent 1

Reference substance name:

-

EC Number:

427-370-1

EC Name:

-

Cas Number:

164288-56-6

Molecular formula:

C21H44N3O3Cl

IUPAC Name:

{[(2-hydroxyethyl)carbamoyl]methyl}dimethyl(3-octadecanamidopropyl)azanium chloride